Featured

BroadOak Capital Partners advised Omixon on its sale of the company to Werfen. Omixon, a privately held company based in Budapest, Hungary, develops and commercializes NGS technology for transplant diagnostics. The full press release is below. October 16, 2024 (Barcelona, Spain): Werfen announced today that it has...

BroadOak Capital Partners invested in PAK Biosolutions to expand their commercial and product development. The full press release is below. Vienna, VA: Today, PAK BioSolutions announced that it has raised $12M from Arboretum Ventures, BroadOak Capital Partners, and other investors to expand commercial and product development efforts...

BroadOak Capital Partners advised LabConnect on its acquisition of A4P Bio. A4P Bio provides bioanalytical project management solutions and consultancy for clinical trials. The full press release is below. JOHNSON CITY, Tenn., April 22, 2024 /PRNewswire/ -- LabConnect has announced the acquisition of A4P Consulting Ltd (A4P), a scientific...

BroadOak Capital Partners advised Biosynth on the acquisition of celares GmbH.  Celares provides customized bioconjugation solutions for Pharma and IVD industries. The full press release is below. Staad, 11th July 2023 – Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce...

Genomenon, a BroadOak portfolio company and a leader in genomic intelligence, acquired Boston Genetics, a genomics interpretation and curation company. The full press release is below. Genomenon Inc., a leader in Genomic Intelligence, today announced it has acquired Boston Genetics, a genomics interpretation and curation company. By...

BroadOak invested in CDI Labs, a provider of serological biomarker discovery services and monoclonal antibody manufacturing and validation services, to expand and scale antibody biomarker discovery platforms. The full press release is below.BALTIMORE, Jan. 9, 2023 /PRNewswire/ -- CDI Laboratories, Inc ("CDI Labs") announced today that it has received...